AVEYABEK

What this means for you

Approved and waiting on proof of use. It will register unless the applicant drops it, and its 04 Sept 2024 filing date already counts against anyone who files later.

Record

Serial number

98733166

Mark type

Stylized text

Filed

04 Sept 2024

Published for opposition

24 Mar 2026

Attorney of record

Marilyn. F. Kelly

Goods and services

• Class 005 — Pharmaceuticals: Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressant preparations, pharmaceutical antibodies for medical use, and immunotherapy preparations for the treatment of cancer; cytokine inhibitory drugs for human use being pharmaceutical preparations for the treatment of cancer; anticoagulants for human use; Pharmaceutical preparations for human use that modulate the immune system for the treatment of immune-system related diseases and disorders; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy preparations for the treatment of cancer; Pharmaceutical and biological preparations for human use, namely, stem cells for medical use; Pharmaceutical preparations for human use for the treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, monoclonal antibodies for medical use; Pharmaceutical preparations for human use for the treatment of neuropsychiatric disorders; therapeutic radiopharmaceutical preparations for human use for the treatment of cancer and solid tumors; diagnostic radiopharmaceutical preparations for human use; diagnostic preparations for human use for medical purposes; radiopharmaceutical preparations for human use in the nature of imaging and detection agents for diagnosing and monitoring cancer; biological preparations for human use in the nature of radio-isotope markers for therapeutic or diagnostic use; Pharmaceutical preparations for human use for the treatment of cystic fibrosis.

Owner

• Celgene Corporation, Princeton, NJ, US
• Celgene Corporation, Princeton, NJ, US

Prosecution history

• 24 Mar 2026 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
• 24 Mar 2026 — PUBLISHED FOR OPPOSITION
• 18 Mar 2026 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
• 03 Mar 2026 — APPROVED FOR PUB - PRINCIPAL REGISTER
• 25 Jun 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
• 25 Jun 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
• 25 Jun 2025 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
• 27 Mar 2025 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
• 27 Mar 2025 — NON-FINAL ACTION E-MAILED
• 27 Mar 2025 — NON-FINAL ACTION WRITTEN
• 27 Mar 2025 — ASSIGNED TO EXAMINER
• 15 Mar 2025 — ASSIGNED TO EXAMINER
• 14 Mar 2025 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
• 04 Sept 2024 — NEW APPLICATION ENTERED